May 9, 2025 The article describes our lab’s clinical trial, GIANT, which seeks to evaluate a novel neoadjuvant immunotherapy approach for glioblastoma, one of the most lethal brain cancers. The study will test a combination of nivolumab and relatlimab, immune checkpoint inhibitors previously used for melanoma, to see if they can improve outcomes when administered […]
March 13, 2023 A study led by Duke University and The University of Sydney found that the COVID-19 pandemic worsened fear and disrupted care for cancer patients, including limited access to clinical trials, visitor restrictions, and reduced social support. Published in Clinical Cancer Research, the findings emphasized that these disruptions impacted patients’ emotional well-being and […]
October 2, 2023 The article describes how new research suggests that fluoxetine (Prozac)—a widely used antidepressant that crosses the blood-brain barrier—may damage tumor cells and make them more sensitive to chemotherapy in patients with recurrent high-grade glioma. A new clinical trial called FLIrT will explore the effectiveness and safety of combining fluoxetine with temozolomide, using tumor […]
June 6, 2024 This article describes the MOAB trial — studying the immunotherapy drug atezolizumab in patients with glioblastoma to determine if it can help them live longer and whether it boosts immune responses against tumors. The trial also investigates tumor mutational burden (TMB) to identify which patients might respond best to the drug, with […]
This page describes the PuMP Trial, which is investigating the safety and effectiveness of MVR-C5252, an experimental oncolytic virus therapy, in adults with recurrent high-grade glioma. Participants will undergo imaging, biopsies, and receive the drug through an implanted catheter system to assess its impact on tumor response and immune activation. Dr. Khasraw is leading the […]
August 26, 2024 This article describes PuMP, a clinical trial that aims to evaluate MVR-C5252 — a genetically modified herpes virus designed to selectively attack recurrent high-grade gliomas and stimulate a patient’s immune system to fight the tumor. Delivered directly into the brain tumor via catheter, the trial progresses through multiple stages to assess safety, […]